Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced neutrophil expansion is worth a clinical trial: G-CSF treatment against COVID-19.
Bioessays
; 43(2): e2000232, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-1372696
ABSTRACT
Immunity against SARS-CoV-2 that is acquired by convalescent COVID-19 patients is examined in reference to (A) the Th17 cell generation system in psoriatic epidermis and (B) a recently discovered phenomenon in which Th17 cells are converted into tissue-resident memory T (TRM ) cells with Th1 phenotype. Neutrophils that are attracted to the site of infection secrete IL-17A, which stimulates lung epithelial cells to express CCL20. Natural Th17 (nTh17) cells are recruited to the infection site by CCL20 and expand in the presence of IL-23. These nTh17 cells are converted to TRM cells upon encounter with SARS-CoV-2 and continue to exist as ex-Th17 cells, which exert Th1-like immunity during a memory response. G-CSF can induce nTh17 cell accumulation at the infection site because it promotes neutrophil egress from the bone marrow. Hence, G-CSF may be effective against COVID-19. Administration of G-CSF to patients infected with SARS-CoV-2 is worth a clinical trial.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Granulocyte Colony-Stimulating Factor
/
Th1 Cells
/
Th17 Cells
/
SARS-CoV-2
/
Neutrophils
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Bioessays
Journal subject:
Biology
/
Molecular Biology
Year:
2021
Document Type:
Article
Affiliation country:
Bies.202000232
Similar
MEDLINE
...
LILACS
LIS